CLINICAL_TRIALS
trial_result
· 2026-03-23
Clinical Trial Update: Early Parkinson's Disease Monotherapy With CVN424 [Phase 2]
Summary
Phase 2 trial of CVN424 as monotherapy for early Parkinson's disease has completed and results have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Cerevance Beta, Inc. | Conditions: Parkinson's Disease | Phase 2 | Status: COMPLETED | Results posted: 2026-03-23